Investment to develop pain therapy
A pain drug development company spun out of The University of Queensland has received a $3.25 million investment commitment to develop its innovative pain therapy.
Spinifex Pharmaceuticals, an emerging biotechnology company specialising in the development of therapeutics for the treatment of neuropathic pain, has attracted investment from a syndicate including Symbiosis Group Limited, Melbourne-based GBS Venture Partners Limited and Uniseed.
Spinifex's core technology relates to the discovery (made by University of Queensland researchers led by Professor Maree Smith) of a novel pathway for the treatment of neuropathic pain. Professor Smith's group successfully validated this pathway using small molecules in well-defined animal models of neuropathic pain.
Rapid blood test can detect iron deficiency in minutes
Scientists have developed a blood test that can detect iron deficiency in just 15 minutes,...
Common carp relatives could help stop virus spreading
While common carp are highly vulnerable to koi herpesvirus, their close relatives including...
Prostate cancer therapy aims for first-in-human clinical studies in 2027
UniQuest, the commercialisation company of UQ, has entered into an exclusive licence agreement...
